RESPIRATORY SYNCYTIAL VIRUS (RSV) Clinical Trial
Official title:
A PHASE 1, OPEN-LABEL, AGE-DESCENDING, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE (RSVpreF) IN CHILDREN 2 TO <18 YEARS OF AGE
The purpose of this study is to learn about the safety and immune activity of the vaccine (called RSVpreF) in children 2 to <18 years of age. This study will identify the dose level to be used in Phase 2/3 trials in this age cohort. All participants will receive one injection of RSVpreF. This study has four study visits, two in-clinic and two telehealth visits. Blood samples will be collected for testing. This study is about 6 months long for each participant and will be conducted in the United States.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02593071 -
Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.
|
Phase 2 | |
| Completed |
NCT02282982 -
Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
|
N/A | |
| Completed |
NCT02266628 -
Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults
|
Phase 2 | |
| Completed |
NCT01704365 -
RSV-F Vaccine Dose Ranging Study in Young Women
|
Phase 2 | |
| Completed |
NCT01709019 -
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
|
Phase 1 | |
| Recruiting |
NCT06185647 -
Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis
|
||
| Recruiting |
NCT04925310 -
Infection With Respiratory Syncytial Virus in Infants
|
||
| Completed |
NCT02968173 -
A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
|
Phase 3 | |
| Active, not recruiting |
NCT06077149 -
Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)
|
Phase 4 | |
| Completed |
NCT02608502 -
A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults
|
Phase 3 | |
| Recruiting |
NCT05047549 -
Community-based RSV Surveillance in Infant Mortality: Minimally Invasive Tissue Sampling Study in Karachi, Pakistan
|
||
| Terminated |
NCT04225897 -
A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.
|
Phase 2 | |
| Recruiting |
NCT06216093 -
Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years
|
Phase 1 | |
| Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
| Completed |
NCT04927793 -
Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT05443607 -
Transplacental Transmission of RSV (TTRSV)
|
||
| Recruiting |
NCT04896853 -
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
|
Phase 1 | |
| Completed |
NCT03916185 -
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT05842967 -
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
|
Phase 3 | |
| Recruiting |
NCT04909021 -
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
|
Phase 1 |